Dr. David Baidal, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 83
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME124485 -
Internal Medicine Physician
FL license ME124485
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 83
- Services billed
- 215
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 29 | 25 |
| Insertion of needle into vein for collection of blood sample | 29 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 24 |
| Hemoglobin a1c level | 27 | 23 |
| Blood glucose (sugar) test performed by hand-held instrument | 25 | 23 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 20 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ozempic (semaglutide) Other prescribers in Miami, FL | 44 |
| Atorvastatin Calcium Other prescribers in Miami, FL | 41 |
| Metformin Hcl Other prescribers in Miami, FL | 38 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in Miami, FL | 37 |
| Rosuvastatin Calcium Other prescribers in Miami, FL | 31 |
| Levothyroxine Sodium Other prescribers in Miami, FL | 29 |
| Trulicity (dulaglutide) Other prescribers in Miami, FL | 29 |
| Mounjaro (tirzepatide) Other prescribers in Miami, FL | 28 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Miami, FL | 23 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Miami, FL | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 5 payments worth $4,833 in total to this clinician.
| Vertex Pharmaceuticals Incorporated | $4,833 |
|---|
| Consulting Fee | $4,723 |
|---|---|
| Travel and Lodging | $102 |
| Food and Beverage | $8.58 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Dec 10, 2025 | Consulting Fee | $3,553 |
| Vertex Pharmaceuticals Incorporated Feb 5, 2025 | Consulting Fee | $1,170 |
| Vertex Pharmaceuticals Incorporated Dec 10, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $58.58 |
| Vertex Pharmaceuticals Incorporated Dec 10, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $43.29 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $6,017 in research payments for these studies, mostly to the institutions running them.
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
Genzyme Corporation · Active, not recruiting · NCT06111586 - A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent…
Sanofi US Services Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.